Most medical products are currently approved through the 510 procedure, a type of regulatory approval process that allows a firm to often avoid clinical trials if it could show that its product is similar to one already being sold. . The Hill: The FDA is currently debating more than 70 changes to the 510 process amid problems that approval guidelines are too lax, and you will be gathering open public input through Oct. 4. AdvaMed supports some changes to the program, such as increased reviewer training, advancement of additional guidance, and greater communication of reviewer decision rationale to prevent delays and inconsistencies in this program.Secondary end factors included the average person components of the principal end point; the composite of loss of life, myocardial infarction, or stroke; and stent thrombosis. Definitions of the ultimate end points are provided in the Supplementary Appendix. All clinical end factors were assessed by the function adjudication committee, whose members were unaware of the study-group assignments. Analyses of most angiographic data had been performed in the angiographic core laboratory of the Cardiovascular Research Foundation.16,17 Statistical Analysis The primary analysis was a noninferiority comparison between the two treatments with regards to the primary end point of major adverse cardiac or cerebrovascular events, based on the intention-to-treat principle.